CN Mobile Logo

Search form


HAART Ups Survival in Primary CNS Lymphoma Patients

HAART Ups Survival in Primary CNS Lymphoma Patients

CHICAGO—Highly active anti-retroviral therapy (HAART) has drastically
reduced the incidence of primary central nervous system (CNS) lymphoma in
HIV-positive individuals at a French hospital and improved survival in
HIV-positive patients who have the brain malignancy.

A poster presented at the Interscience Conference on Antimicrobial Agents
and Chemotherapy (ICAAC abstract 250) traced patients with primary CNS lymphoma
over a 17-year period.

Only eight cases of the disease have occurred since HAART was introduced in
1996, said Phillippe Bossi, MD, of Pitie-Salpetriere Hospital. Median survival,
which was only 1 month prior to the introduction of HAART, increased to 10
months between 1996 and 1999, he said.

The poster presented findings from a retrospective analysis of 80 patients
with primary CNS lymphoma out of a total of 2,263 individuals with AIDS who
were followed from 1983 to 1999 at Pitie-Salpetriere Hospital. Between 1988 and
1991, the incidence of primary CNS lymphoma rose steadily, reaching a peak of
39 per 1,000 patient-years. The incidence has declined since 1991, dropping to
1.9 per 1,000 patient-years in 1999.

In 29 patients (36%), primary CNS lymphoma was the first indication of AIDS.
The vast majority of patients were male (92%). A total of 66 patients (82%)
received HAART.

Median survival increased in particular for patients who had high CD4+ cell
counts at the time primary CNS lymphoma was diagnosed. Of the 8 patients
diagnosed since 1996, four lived less than 5 months after diagnosis. These
patients had CD4+ cell counts ranging from 1 to 4/µL at diagnosis, and the count did not change from diagnosis to death.

In contrast, the other four patients, with median CD4+ cell counts of
95/µL, lived longer than 15 months, and their cell counts had increased to
241/µL at the time of their death or the last measurement. Two of these
patients were still alive 38 and 44 months after diagnosis and use of HAART.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.